U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
Iberdomide has the potential to be the first approved CELMoD agent The U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication... Read more.
Palantir Wins Dresner Advisory Services 2025 Technology Innovation and Application Innovation Awards in Multiple Categories
DENVER–(BUSINESS WIRE)–Palantir Technologies Inc. (NASDAQ: PLTR), a leading provider of AI systems, today announced it has been recognized as a winner... Read more.
Janus International Group to Report Fourth Quarter and Full Year 2025 Results on March 4, 2026
TEMPLE, Ga.–(BUSINESS WIRE)–Janus International Group, Inc. (NYSE: JBI) (“Janus” or the “Company”), a leading global provider of building product... Read more.
USA Compression Partners Reports Fourth-Quarter 2025 Results and Provides 2026 Outlook; Achieves Record Results
DALLAS–(BUSINESS WIRE)–USA Compression Partners, LP (NYSE: USAC) (“USA Compression” or the “Partnership”) announced today its financial and operating... Read more.
DNOW Announces Fourth Quarter and Full-Year 2025 Earnings Conference Call
HOUSTON–(BUSINESS WIRE)–DNOW Inc. (NYSE:DNOW) has scheduled a conference call to discuss the results for the fourth quarter and full-year 2025 on Friday,... Read more.
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in progression-free survival in BRAF V600E-mutant... Read more.
Henry Schein One Connects Align Technology’s iTero™ Scanners to Dentrix, Dentrix Ascend, and Dentally, Advancing a More Connected Global Standard of Care
New integration unifies diagnosis, treatment planning, and practice management AMERICAN FORK, Utah–(BUSINESS WIRE)–Henry Schein One today announced a... Read more.
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect that has... Read more.
Anaergia, Eni and CREvolution Unveil Breakthrough Platform to Scale Demand for Biodiesel and SAF
Anaergia, Eni and CREvolution Launch Breakthrough Circular Economy Project at Gela Biorefinery, a first-of-its-kind system positioned to meet surging global demand... Read more.
Teleflex Announces Fourth Quarter 2025 Earnings Conference Call Information
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter 2025 financial results and provide... Read more.